technology Essay -- essays research papers

THURSDAY, July 21 (HealthDay News) -- Following surgery, a single dose of the cancer drug carboplatin is just as effective, and less toxic, than the standard three weeks of radiation therapy traditionally used to fight stage 1 seminoma, a form of testicular cancer, British researchers report. In addition, treatment with carboplatin results in the development of fewer new seminomas compared with traditional radiation therapy, according to the report in the July 23 issue of The Lancet. For the past half-century, the standard care for seminoma has been to remove the cancerous testicle, usually followed by three weeks of radiotherapy. However, the researchers point to previous studies that found that patients followed for up to 30 years post-treatment still faced an increased risk of cancer in other organs, as well as heart disease. Patients may finally have a new option, however. "We have defined a new standard for patients with testicular cancer," said lead author Dr. Tim Oliver, a professor of medical oncology at St. Bartholomew's and The London School of Medicine. "It's proven to be as safe as radiation, and it's less toxic." In their study, Oliver and colleagues randomly assigned nearly 1,500 patients with stage 1 seminoma to a single course of post-surgery carboplatin or radiation therapy. After three years of follow-up, they report that survival without relapse was similar in both groups -- 94.8 percent among those who received carboplatin compare...